DeepKinase
嘉华药锐
DeepKinase (嘉华药锐) is a precision oncology diagnostics company co-founded by Xiao Yun, a Peking University Yuanpei Program graduate with over a decade of in-vitro diagnostics industry experience at Abbott, Wantai, Fresenius, and STAGO . FreeS Fund (峰瑞资本) invested at the angel stage and continued to back the company through its Series A and A+ rounds, which together raised over 100 million RMB as of mid-2023 . The company was among the biotech firms FreeS highlighted for their resilience in securing funding during the challenging 2022 market environment .
AI-generated — may contain errors, please verify.
Coverage
From Angel to G+ Round: 5 Early-Stage FreeS Fund Portfolio Companies Raise Over 3 Billion RMB | FreeS Family Funding News · Vol 14
Looking forward to working alongside more outstanding founders.
峰瑞资本·The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
峰瑞资本·How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
峰瑞资本·Women Rising: 18 Voices from the World of Entrepreneurship | FreeS Fund International Women's Day Special
The traits that lead to success know no gender. May your journey of discovery be filled with wonder.
峰瑞资本·Beyond the "Narrow Door": A Real-World Portrait of Early-Stage Frontier Biotech Entrepreneurship in China | FreeS Fund 2020 Biotech Summit Registration Now Open
Will Today’s US Biotech Become China’s Tomorrow?
峰瑞资本·A Job Posting, Three Events | Frees Fund
Looking forward to your participation.
峰瑞资本·FreeS Fund Healthcare Open Day Is Here: Entering the Grand Era of Biomedical Innovation
Looking for China's Genentech, Moderna, Alnylam, Spark, Nimbus Therapeutics
峰瑞资本·FreeS Fund received eight recognitions from institutions including *Fortune* (Chinese edition), 36Kr, and the Fund of Funds Alliance.
Do what's right, not what's easy.
峰瑞资本·
